Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks to Buy That Wall Street Thinks Will Soar 50% or More

By Keith Speights - Apr 14, 2021 at 6:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Analysts' enthusiasm for these stocks appears to be justified.

Wall Street analysts aren't always right. They can have biases for or against certain stocks. In some cases, they have a clear motivation to serve as cheerleaders for specific stocks. But these knocks against analysts don't mean that they don't often make good calls.

Sometimes, analysts are super-bullish about individual stocks that really are promising picks. Here are three stocks to buy that Wall Street analysts think will soar 50% or more.

Three blue lines with arrows pointing up

Image source: Getty Images.

Nano-X Imaging

The average analysts' one-year price target for Nano-X Imaging (NNOX -3.81%) (Nanox) reflects a 70% premium to the current price of the stock. There's a pretty clear path for Nanox to hit that target.

Earlier this month, the company received U.S. Food and Drug Administration (FDA) clearance for its single-source Nanox.ARC digital X-ray device. Nanox plans to begin shipping systems in the fourth quarter of this year. Even more importantly, Nanox expects to file for FDA clearance of its multi-source Nanox.ARC X-ray device this year. This is the system that the company hopes will be its real commercial winner. 

The opportunities for Nanox are ginormous if it gets a green light from the FDA for its multi-source device. Current X-ray systems cost millions of dollars and have a large footprint. Nanox's digital X-ray device will cost significantly less (in the tens of thousands of dollars) and are small. The company's technology could greatly expand the $21 billion global medical imaging market. 

To be sure, Nanox remains a risky stock that isn't well suited for all investors. There's a possibility that the company won't secure FDA clearance for its multi-source Nanox.ARC device. However, for aggressive investors, this stock could deliver massive gains that are a lot bigger than Wall Street analysts project if all goes well.

Novavax

Novavax (NVAX 11.12%) shares have soared more than 70% so far this year. Wall Street thinks there's more room to run: The average price target for the biotech stock is over 50% higher than Novavax's current price.

Analysts' bullish takes on Novavax appear to be warranted. The company reported positive results from a late-stage study of its COVID-19 vaccine in March, with an overall efficacy of 89.7% and efficacy of 96.4% against the original COVID-19 strain. 

Novavax hopes to win Emergency Use Authorization (EUA) in the U.K. soon. It would like to be able to file for EUA in the U.S. based on the late-stage results from its U.K. study. Even if the FDA doesn't allow that to happen, though, the biotech should wrap up another late-stage study of its COVID-19 vaccine conducted in the U.S. and Mexico in the second quarter of 2021. 

Big bucks will pour into Novavax's coffers if it secures authorizations from regulatory agencies for its COVID-19 vaccine. The company already has supply deals in place for around 300 million doses.

Trupanion

Analysts also foresee success for Trupanion (TRUP 1.25%). The average Wall Street price target for the pet medical insurance stock reflects a 60% upside potential.

Trupanion was a lot closer to analysts' target earlier this year. However, the company reported mixed fourth-quarter results in early February and said that its spending would increase in 2021 on pre-revenue initiatives. That update combined with a market rotation away from growth stocks caused Trupanion's shares to plunge more than 35%.

However, the growth prospects for Trupanion are still very good. Pet ownership is increasing. The U.S. and Canadian pet medical insurance markets are greatly underpenetrated. Trupanion expects its subscription revenue to jump around 25% this year.

Beyond 2021, Trupanion's relationship with Aflac could begin to pay off. The big supplemental insurance company bought nearly 10% of Trupanion last year. Aflac plans to offer Trupanion's pet insurance to large and medium-sized businesses beginning in 2022 and subsequently expand into the small business market. This stock shouldn't remain beaten down for much longer. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trupanion Stock Quote
Trupanion
TRUP
$61.01 (1.25%) $0.75
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$57.15 (11.12%) $5.72
Aflac Incorporated Stock Quote
Aflac Incorporated
AFL
$56.24 (1.65%) $0.91
Nano-X Imaging Ltd. Stock Quote
Nano-X Imaging Ltd.
NNOX
$10.87 (-3.81%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.